ORIC

7.3504.55%
DG

Dominic G. Piscitelli

Chief Financial Officer

Mr. Dominic G. Piscitelli, M.B.A., C.P.A. has been Independent Director at Celyad Oncology SA (formerly known as Celyad SA) since May 5, 2020. He is Director of Alterome Therapeutics, Inc. Mr. Piscitelli has been Chief Financial Officer of ORIC Pharmaceuticals, Inc. since September 2019. He joined the ORIC Pharmaceuticals, Inc. in September 2019. Mr. Piscitelli served as an Executive Officer at AnaptysBio, Inc. since August 16, 2019 until September 9, 2019 and served as its Chief Financial Officer since January 11, 2017 until August 16, 2019. Previously, he served as Senior Director of Collaborations and Operations Finance at Astellas Pharma. Mr. Piscitelli has extensive experience, including debt and equity financings, in-licensing transactions, acquisitions, marketing partnerships and commercial product launches, including playing a part in the commercials launches of XTANDI. From 2012 until 2017, Mr. Piscitelli was Vice President of Finance, Strategy and Investor Relations at Medivation and played a key role in its acquisition by Pfizer Inc. in 2016. From 2001 to 2011, Mr. Piscitelli served in various roles of increasing responsibility culminating as the Vice President of Treasury & Management Finance at OSI Pharmaceuticals, Inc. and played a significant role in its acquisition by Astellas Pharmaceuticals. Mr. Piscitelli began his career with KPMG and is a Certified Public Accountant. He earned a bachelor’s degree in accounting and an MBA from Hofstra University (New York).

Positions